- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06850038
En studie som observerer langsiktig, effektivitet og sikkerhet for Odevixibat (Bylvay) hos pasienter med Alagille syndrom (ALG) som får pågående behandling
Prospektiv registerbasert studie Evaluering av effektiviteten og sikkerheten til Odevixibat hos deltakere med Alagille syndrom (ALGS)
This study will collect information from patients with Alagille syndrome (ALGS) as they use odevixibat (Bylvay) in their daily lives.
Odevixibat is a medicine that helps patients with ALGS, a rare disease that harms their liver and causes itching.
The main aim of this study is to observe the long-term, everyday effectiveness and safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.
Studieoversikt
Status
Forhold
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Ipsen Recruitment Enquiries
- Telefonnummer: See email
- E-post: clinical.trials@ipsen.com
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90027
- Rekruttering
- Children's Hospital Los Angeles
-
San Francisco, California, Forente stater, 94158
- Rekruttering
- UCSF Benioff Children's Hospital
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64108
- Rekruttering
- The Children's Mercy Hospital
-
St Louis, Missouri, Forente stater, 63104
- Rekruttering
- SSM Health Cardinal Glennon Children's Hospital
-
-
New York
-
New York, New York, Forente stater, 10016
- Rekruttering
- NYU Langone - NYU Grossman School of Medicine
-
New York, New York, Forente stater, 10032
- Rekruttering
- Columbia University Medical Center - Morgan Stanley Children's Hospital of NewYork - Presbyterian (MS-CHONY)
-
-
Tennessee
-
Memphis, Tennessee, Forente stater, 38105
- Rekruttering
- Le Bonheur Children's Hospital
-
-
Texas
-
Dallas, Texas, Forente stater, 75246
- Rekruttering
- Children's Medical Center Of Dallas
-
El Paso, Texas, Forente stater, 79902
- Rekruttering
- Proactive El Paso,LLC
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84113
- Har ikke rekruttert ennå
- Primary Children's Hospital (PCH) - Intermountain Healthcare/University of Utah
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patients diagnosed with ALGS who start treatment with odevixibat (Bylvay) will be enrolled into the registry. Patients who started odevixibat treatment before the implementation of the registry study may also be enrolled.
Beskrivelse
Inclusion Criteria:
- Diagnosed with ALGS.
- On (or starting) active odevixibat treatment.
- Signed informed consent and assent, as appropriate. Consent/assent from the participant or legal representative should be obtained, as appropriate, before any study data collection is conducted. Participants who turn 18 years of age (or legal age per country) while participating in the study will be required to provide consent for themselves.
Exclusion Criteria:
- Currently participating in a clinical trial with odevixibat.
- Currently participating in any interventional clinical trial for ALGS.
- Have any contraindication to odevixibat as per the locally approved label.
- Had liver transplant before enrolment
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: OTHER
- Tidsperspektiver: PROSPECTIVE
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Prosentandel av deltakere med Alagille syndrom (ALG) som blir behandlet med Odevixibat og gjennomgår galle -avledningskirurgi eller levertransplantasjon.
Tidsramme: Fra første dose til slutten av studien (ca. 5 års datainnsamling)
|
Fra første dose til slutten av studien (ca. 5 års datainnsamling)
|
|
|
Surgical biliary diversion-free survival
Tidsramme: From first dose to end of study (approximately 5 years data collection)
|
Defined as time from the start of odevixibat treatment to the first occurrence of surgical biliary diversion or death. |
From first dose to end of study (approximately 5 years data collection)
|
|
Liver transplant-free survival
Tidsramme: From first dose to end of study (approximately 5 years data collection)
|
Defined as time from the start of odevixibat treatment to the first occurrence of liver transplant or death. |
From first dose to end of study (approximately 5 years data collection)
|
|
Overall survival
Tidsramme: From first dose to end of study (approximately 5 years data collection)
|
Defined as time from the start of odevixibat treatment to death. |
From first dose to end of study (approximately 5 years data collection)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline in Weight
Tidsramme: From first dose to end of study (approximately 5 years data collection)
|
This endpoint will measure the change in participants' weight from baseline, reported as standard-deviation scores (z-scores) to account for age and sex-specific growth variations. |
From first dose to end of study (approximately 5 years data collection)
|
|
Change from Baseline in Height
Tidsramme: From first dose to end of study (approximately 5 years data collection)
|
This endpoint will measure the change in participants' height from baseline, reported as standard-deviation scores (z-scores) to account for age and sex-specific growth variations. |
From first dose to end of study (approximately 5 years data collection)
|
|
Percentage of participants with Adverse Events (AEs) associated with fat-soluble vitamin (FSV) deficiencies and their possible sequelae.
Tidsramme: From signing of the Informed Consent Form (ICF) to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the Informed Consent Form (ICF) to 180 days after the last dose intake of odevixibat
|
|
Percentage of participants with suspected hepatotoxic Adverse events (AEs) requiring interruption of odevixibat
Tidsramme: From signing of the ICF to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the ICF to 180 days after the last dose intake of odevixibat
|
|
Percentage of participants with bleeding AEs
Tidsramme: From signing of the ICF to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the ICF to 180 days after the last dose intake of odevixibat
|
|
Percentage of participants with AEs
Tidsramme: From signing of the ICF to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the ICF to 180 days after the last dose intake of odevixibat
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Ipsen Medical, Director, Ipsen
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Kardiovaskulære sykdommer
- Genetiske sykdommer, medfødte
- Sykdommer i fordøyelsessystemet
- Galleveissykdommer
- Leversykdommer
- Medfødte abnormiteter
- Kardiovaskulære abnormiteter
- Hjertefeil, medfødt
- Abnormiteter, flere
- Galleveissykdommer
- Kolestase, intrahepatisk
- Kolestase
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Alagille syndrom
Andre studie-ID-numre
- CLIN-60240-033
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
IPD-delingstidsramme
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Tilgangskriterier for IPD-deling
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .